Cable Hill Partners’s Aratana Therapeutics, Inc. PETX Stock Holding History

Cable Hill Partners’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,000	Closed	-$15K	–	948
2018 Q1	$15K	Buy	3,000 +1,000	+50%	+$4.46K	0.01%	405
2017 Q4	$11K	Buy	2,000 +1,000	+100%	+$6.12K	﹤0.01%	566
2017 Q3	$6K	Hold	1,000	–	–	﹤0.01%	735
2017 Q2	$7K	Buy	+1,000	New	+$6.15K	﹤0.01%	500

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cable Hill Partners's PETX Position: Q2 2018 in Review

Cable Hill Partners sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2018, closing a stake of 3,000 shares — an estimated $15K sold.

Cable Hill Partners first reported a position in PETX in Q2 2017 and held it in 4 quarters. The position peaked at $15K in Q1 2018. 105 funds tracked by Wall St. Rank hold PETX as of Q2 2018.

Cable Hill Partners reported no remaining Aratana Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Cable Hill Partners sold 3,000 Aratana Therapeutics, Inc. shares in Q2 2018, an estimated $15K.
Cable Hill Partners first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 4 quarters.
Cable Hill Partners's Aratana Therapeutics, Inc. position peaked at $15K in Q1 2018.
105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2018.

Based on Cable Hill Partners's 13F filing for Q2 2018, filed 3 Aug 2018.